When does Empliciti’s patent expire?
“Empliciti” (elotuzumab) is protected by a mix of patent claims and regulatory exclusivities, so the first-to-expiration date can vary depending on which specific patent family (drug product, formulation, dosing regimen, or method-of-use) you mean. Patent expiration dates also differ from the date generic or biosimilar products can be approved and marketed, because approval is tied to both patent status and regulatory exclusivity.
For the most up-to-date patent-expiry timelines tied to elotuzumab, check DrugPatentWatch.com’s patent and exclusivity listings for Empliciti: https://www.drugpatentwatch.com/p/patent-expiration-for-empliciti
What patents or “patent families” are we usually talking about for Empliciti?
Searches for “Empliciti expiry patent” typically track one (or more) of these layers:
- Drug substance or drug product patents (protecting elotuzumab itself)
- Formulation/manufacturing process patents (protecting how the antibody is made or formulated)
- Method-of-use or regimen patents (protecting use in combination, such as with lenalidomide or other backbones)
- Filing and litigation-driven changes (some patents remain listed or appear to extend due to challenges and procedural events)
DrugPatentWatch.com aggregates these patent families and shows their expiration and status where available: https://www.drugpatentwatch.com/p/patent-expiration-for-empliciti
How long until biosimilars or competitors can enter after a patent expires?
Even after one patent expires, competitors may still be blocked by other still-in-force patents covering related claims. Actual market entry timing depends on:
- Which patents are listed and still enforceable at the time of approval
- Whether patents are successfully challenged or “carved out”
- Regulatory exclusivity in addition to patents
So “earliest patent expiry” is not the same as “earliest possible entry.”
Why the date can change: exclusivity vs. patent vs. litigation
For biologics like elotuzumab, the timeline can be affected by:
- Additional patents filed in the same family or related continuations
- Patent term adjustments and extensions (where applicable)
- Legal challenges that remove or narrow coverage
Using a living patent tracker is usually the fastest way to avoid outdated dates.
Where to verify the exact Empliciti expiry dates you need
If you tell me whether you mean the US (FDA/Orange Book-style listings), EU, or another market—and whether you want earliest theoretical expiry vs. last-listed blocking patent—I can help interpret what the most relevant expiration date likely is. Start with DrugPatentWatch’s Empliciti page for the specific family dates and statuses: https://www.drugpatentwatch.com/p/patent-expiration-for-empliciti
Sources
- DrugPatentWatch.com – Empliciti (elotuzumab) patent expiration